Trials / Completed
CompletedNCT01144247
Cellular Immunotherapy Study for Brain Cancer
A Phase I Clinical Trial Evaluating Cellular Immunotherapy With Intratumoral Alloreactive Cytotoxic T Lymphocytes and Interleukin-2 for the Treatment of Recurrent Malignant Gliomas or Meningiomas
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Jonsson Comprehensive Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study to determine if treating recurrent malignant gliomas with another person's (donor) immune system cells known as aCTL cells, will be safe. This study will also try to determine if persons who receive aCTL's are more or less likely to survive their brain tumor than persons who had similar tumors in the past. Approximately 15 patients will be enrolled at UCLA.
Conditions
- Gliomas
- Anaplastic Astrocytoma
- Anaplastic Oligodendroglioma
- Anaplastic Mixed Glioma
- Glioblastoma Multiforme
- Malignant Meningioma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | alloreactive CTL | cellular immunotherapy with alloCTL |
Timeline
- Start date
- 2010-07-01
- Primary completion
- 2015-07-01
- Completion
- 2015-07-01
- First posted
- 2010-06-15
- Last updated
- 2016-05-27
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01144247. Inclusion in this directory is not an endorsement.